We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+1.66%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.45B
AUM Growth
+$98.6M
Cap. Flow
+$39.6M
Cap. Flow %
1.62%
Top 10 Hldgs %
39.51%
Holding
166
New
25
Increased
26
Reduced
19
Closed
10

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$38M
2
COR icon
Cencora
COR
+$30.2M
3
CVS icon
CVS Health
CVS
+$22.3M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$21M
5
GILD icon
Gilead Sciences
GILD
+$16M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$36M
2
MDVN
MEDIVATION, INC.
MDVN
+$23.3M
3
NVO
Novo Nordisk
NVO
+$16M
4
VTR icon
Ventas
VTR
+$14.3M
5
DOC
PHYSICIANS REALTY TRUST
DOC
+$13.4M

Sector Composition

Rank Sector Weight
1 Healthcare 86.46%
2 Real Estate 2.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$163B
$210M 8.55%
2,511,731
+180,500
+8% +$16M
CELG
2
DELISTED
Celgene Corp
CELG
$138M 5.63%
1,398,789
-348,445
-20% -$36M
BIIB icon
3
Biogen
BIIB
$30.7B
$109M 4.45%
450,533
– –
AGN
4
DELISTED
Allergan plc
AGN
$107M 4.38%
463,886
+54,300
+13% +$12.5M
VRTX icon
5
Vertex Pharmaceuticals
VRTX
$122B
$88.9M 3.63%
1,033,503
– –
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$79.6M 3.25%
681,805
+45,000
+7% +$6.38M
INCY icon
7
Incyte
INCY
$24.9B
$70.4M 2.87%
880,461
-76,000
-8% -$5.9M
MDT icon
8
Medtronic
MDT
$110B
$59.3M 2.42%
683,704
+126,600
+23% +$10.2M
REGN icon
9
Regeneron Pharmaceuticals
REGN
$77.4B
$53.9M 2.2%
154,266
– –
PFE icon
10
Pfizer
PFE
$142B
$52.2M 2.13%
1,563,389
-346,471
-18% -$11.1M
ILMN icon
11
Illumina
ILMN
$31B
$52.1M 2.13%
381,762
+23,130
+6% +$3.29M
BMRN icon
12
BioMarin Pharmaceuticals
BMRN
$11.7B
$50.9M 2.08%
653,845
+57,700
+10% +$4.91M
AMGN icon
13
Amgen
AMGN
$209B
$50.5M 2.06%
331,740
+10,100
+3% +$1.57M
UNH icon
14
UnitedHealth
UNH
$383B
$46.8M 1.91%
331,100
-78,000
-19% -$10.4M
MRK icon
15
Merck
MRK
$321B
$46M 1.88%
835,882
+122,092
+17% +$6.5M
JNJ icon
16
Johnson & Johnson
JNJ
$617B
$40.9M 1.67%
337,312
-37,776
-10% -$4.29M
LLY icon
17
Eli Lilly
LLY
$1.03T
$39.6M 1.62%
502,567
+85,400
+20% +$6.43M
ABT icon
18
Abbott
ABT
$183B
$37.5M 1.53%
+953,500
New +$38M
SHPG
19
DELISTED
Shire pic
SHPG
$37.1M 1.52%
201,713
– –
NBIX icon
20
Neurocrine Biosciences
NBIX
$18.7B
$34.9M 1.42%
767,022
+455,562
+146% +$21M
TEVA icon
21
Teva Pharmaceuticals
TEVA
$41.2B
$33.8M 1.38%
671,958
– –
VTRS icon
22
Viatris
VTRS
$20.7B
$31.2M 1.28%
722,552
+104,600
+17% +$4.63M
ALKS icon
23
Alkermes
ALKS
$8.39B
$30M 1.22%
693,844
+111,900
+19% +$4.62M
COR icon
24
Cencora
COR
$60.7B
$29.9M 1.22%
+376,500
New +$30.2M
MOH icon
25
Molina Healthcare
MOH
$10.2B
$26.8M 1.1%
537,901
+190,000
+55% +$10.2M
1
2 3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2016 Portfolio in Review

As of Q2 2016, Tekla Capital Management held 166 positions worth $2.45B, up 4.2% from $2.35B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q2 2016 filing shows 25 new, 26 increased, 19 reduced and 10 closed positions. Its largest new stake was Abbott: 953,500 shares worth $37.5M. The largest sale was Celgene Corp, an estimated $36M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 87% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2016 buy was Abbott: 953,500 shares worth $37.5M.
  • Tekla Capital Management added most to Neurocrine Biosciences in Q2 2016, an estimated $21M increase.
  • Tekla Capital Management's biggest Q2 2016 reduction was Celgene Corp, cutting an estimated $36M.
  • Tekla Capital Management fully exited Novo Nordisk in Q2 2016, selling an estimated $16M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.45B portfolio in Q2 2016.
  • Tekla Capital Management opened 25 new positions and closed 10 in Q2 2016.
  • Tekla Capital Management's portfolio value rose 4.2% quarter-over-quarter to $2.45B.

Based on Tekla Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.